IL6R and COVID-19: Moreover, the use of tocilizumab, a blocker of IL-6 receptor (IL-6R), has been recommended for severe cases of COVID-19 (Huang et al., 2020; Ruan et al., 2020; Wu et al., 2020a; Angriman et al., 2021; Galván-Román et al., 2021; Mcelvaney et al., 2021).